Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Lonza Group    LONN   CH0013841017

LONZA GROUP

(LONN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Lonza : Announces Short, Routine Shutdown of Niacinamide Plant in Nansha for Maintenance

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/23/2019 | 10:02am EST

Basel - Lonza today announced that it will shut down its production of Niacinamide (vitamin B3) in Nansha (CN) in November and December 2019 for six weeks to perform routine maintenance and process optimization.

During this period, Lonza will fulfill all confirmed orders and contractual obligations.

About Lonza

Lonza is an integrated solutions provider that creates value along the Healthcare Continuum . Through our Pharma Biotech & Nutrition segment and our Specialty Ingredients segment businesses, we harness science and technology to serve markets along this continuum. We focus on creating a healthy environment, promoting a healthier lifestyle and preventing illness through consumers' preventive healthcare, as well as improving patient healthcare by supporting our customers to deliver innovative medicines that help treat or even cure severe diseases.

Patients and consumers benefit from our ability to transfer our pharma know-how to the healthcare, hygiene and fast-moving consumer goods environment and to the preservation and protection of the world where we live.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 15,500 full-time employees worldwide at the end of 2018. The company generated sales of CHF 5.5 billion in 2018 with a CORE EBITDA of CHF 1.5 billion.

Contact:

Dr. Kristin Koehler

Tel: +41 61 316 8782

Email: kristin.koehler@lonza.com

Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ('SGX-ST'). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.

(C) 2019 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on LONZA GROUP
11/27Pfizer, Novartis lead $2 billion spending spree on gene therapy production
RE
11/21LONZA : Navrogen Inc. and Lonza Sign Agreement to Use Lonza's GS Gene Expression..
AQ
11/14LONZA : New eCHO Basal Medium and Feed Facilitates Late-Stage Cell Viability and..
AQ
11/12Board Announcement
TE
11/06CRYOPORT : Lonza Partners with Cryoport and Strengthens its 'Vein-to-vein' Deliv..
AQ
10/29LONZA : to Host New Webinar 'Paper to EBR in 9 Months How a Strong Collaboration..
AQ
10/23LONZA : Announces Short, Routine Shutdown of Niacinamide Plant in Nansha for Mai..
AQ
10/18MESOBLAST : and Lonza Enter GVHD Commercial Manufacturing Agreement
AQ
10/17LONZA : Strengthens Sports Nutrition Portfolio with the Launch of Vegan MuscleGu..
AQ
10/17MESOBLAST : and Lonza Enter into Agreement for Commercial Manufacture of Mesobla..
AQ
More news
Financials (CHF)
Sales 2019 5 898 M
EBIT 2019 1 202 M
Net income 2019 723 M
Debt 2019 3 213 M
Yield 2019 0,85%
P/E ratio 2019 34,6x
P/E ratio 2020 28,8x
EV / Sales2019 4,77x
EV / Sales2020 4,41x
Capitalization 24 917 M
Chart LONZA GROUP
Duration : Period :
Lonza Group Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LONZA GROUP
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 374,86  CHF
Last Close Price 335,60  CHF
Spread / Highest target 37,7%
Spread / Average Target 11,7%
Spread / Lowest Target -18,1%
EPS Revisions
Managers
NameTitle
Marc Funk Chief Executive Officer
Albert M. Baehny Chairman
Rodolfo Savitzky Chief Financial Officer
Patrick Aebischer Vice Chairman
Margot A. Scheltema Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
LONZA GROUP32.08%25 344
IQVIA HOLDINGS INC.24.69%28 106
INCYTE CORPORATION43.91%19 711
SEATTLE GENETICS, INC.100.97%19 516
CELLTRION, INC.--.--%18 622
GALAPAGOS133.43%13 527